31 min
E99 - An Untold Story: Ozempic and AI Flipping the Future Economy In Search of Green Marbles
-
- Investing
In this episode of Green Marbles, recorded on September 14th, Jordi and G3 discuss the explosive category of drugs that were first put on the market to address diabetes, but are now also being used for weight loss. The most notable of these drugs is Ozempic. They proceed to talk about this drug and others from a longevity, economic and market perspective.
Please check important disclosures at the end of the episode and take special note that this podcast is for informational purposes only.
Timestamps:
What inspired Jordi to approach G3 about doing an episode on weight loss drugs? [1:37]When did the Ozempic frenzy begin? [6:47]How does Jordi connect longevity, Ozempic and AI? [9:05]What are some potential near-term economic and market impacts of Ozempic? [17:30]Does Jordi believe that the Federal Reserve is taking into account how health care innovation is impacting our economy? [23:40]
Resources:
The economic value of targeting agingAI and the COVID-19 Vaccine: Moderna’s Dave JohnsonGoogle DeepMind’s AlphaFoldNovo Nordisk dethrones LVMH as Europe’s most valuable companyLilly's Phase 2 retatrutide results published in The New England Journal of Medicine
Disclosures: This podcast and associated content (collectively, the “Post”) are provided to you by Weiss Multi-Strategy Advisers LLC (“Weiss”). The views expressed in the Post are for informational purposes only and are subject to change without notice. Information in this Post has been developed internally and is based on market conditions as of the date of the recording from sources believed to be reliable. Nothing in this Post should be construed as investment, legal, tax, or other advice and should not be viewed as a recommendation to purchase or sell any security or adopt any investment strategy. Past performance is no guarantee of future results. You should consult your own advisers regarding business, legal, tax, or other matters concerning investments. Any health-related information shared on the podcast is not intended as medical advice or for use in self-diagnosis or treatment. Please consult a qualified healthcare professional before acting upon any health-related information on the podcast. Weiss has no control over information at any external site hyperlinked in this Post. Weiss makes no representation concerning and is not responsible for the quality, content, nature, or reliability of any hyperlinked site and has included hyperlinks only as a convenience. The inclusion of any external hyperlink does not imply any endorsement, investigation, verification, or ongoing monitoring by Weiss of any information in any hyperlinked site. In no event shall Weiss be responsible for your use of a hyperlinked site. This is not intended to be an offer or solicitation of any security. Please visit www.gweiss.com to review related disclosures and learn more about Weiss.
In this episode of Green Marbles, recorded on September 14th, Jordi and G3 discuss the explosive category of drugs that were first put on the market to address diabetes, but are now also being used for weight loss. The most notable of these drugs is Ozempic. They proceed to talk about this drug and others from a longevity, economic and market perspective.
Please check important disclosures at the end of the episode and take special note that this podcast is for informational purposes only.
Timestamps:
What inspired Jordi to approach G3 about doing an episode on weight loss drugs? [1:37]When did the Ozempic frenzy begin? [6:47]How does Jordi connect longevity, Ozempic and AI? [9:05]What are some potential near-term economic and market impacts of Ozempic? [17:30]Does Jordi believe that the Federal Reserve is taking into account how health care innovation is impacting our economy? [23:40]
Resources:
The economic value of targeting agingAI and the COVID-19 Vaccine: Moderna’s Dave JohnsonGoogle DeepMind’s AlphaFoldNovo Nordisk dethrones LVMH as Europe’s most valuable companyLilly's Phase 2 retatrutide results published in The New England Journal of Medicine
Disclosures: This podcast and associated content (collectively, the “Post”) are provided to you by Weiss Multi-Strategy Advisers LLC (“Weiss”). The views expressed in the Post are for informational purposes only and are subject to change without notice. Information in this Post has been developed internally and is based on market conditions as of the date of the recording from sources believed to be reliable. Nothing in this Post should be construed as investment, legal, tax, or other advice and should not be viewed as a recommendation to purchase or sell any security or adopt any investment strategy. Past performance is no guarantee of future results. You should consult your own advisers regarding business, legal, tax, or other matters concerning investments. Any health-related information shared on the podcast is not intended as medical advice or for use in self-diagnosis or treatment. Please consult a qualified healthcare professional before acting upon any health-related information on the podcast. Weiss has no control over information at any external site hyperlinked in this Post. Weiss makes no representation concerning and is not responsible for the quality, content, nature, or reliability of any hyperlinked site and has included hyperlinks only as a convenience. The inclusion of any external hyperlink does not imply any endorsement, investigation, verification, or ongoing monitoring by Weiss of any information in any hyperlinked site. In no event shall Weiss be responsible for your use of a hyperlinked site. This is not intended to be an offer or solicitation of any security. Please visit www.gweiss.com to review related disclosures and learn more about Weiss.
31 min